In tumor models, comparative pharmacokinetics, biodistribution, and efficacy studies demonstrated that HSA-PLA (PTX) nanoparticles reduce premature drug release, resulting in greater tumor exposure (129 ± 3 vs. 90 ± 12 μg·h/g, p < 0.01) and superior antitumor efficacy compared with Abraxane. This evidence concerns the gene ALB and neoplasm.